Latest Conference Articles

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.

Dr Sands on the Evolving Role of ADCs in SCLC Management

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Dr Sabari on Barriers to Biomarker Testing in NSCLC

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

Sonya Reid, MD, MPH, discusses barriers to universal germline testing utilization in breast cancer, particularly among underserved populations.

Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium

Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

Circulating tumor DNA is in constant flux, rendering its evaluation potentially useful in metastatic breast cancer management.

De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH, discusses the use of HER2-directed therapy in the curative setting for HER2-positive breast cancer.

Dr Feldman on New Approaches for Decreasing the Risk of Breast Cancer–Related Lymphedema

Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.

Dr Mukhtar on Challenges in the Diagnosis and Management of Invasive Lobular Carcinoma

Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.

Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

AE Management and Prevention Strategies for ADCs, Immunotherapy in Breast Cancer

Hope Rugo, MD, discusses the management of treatment-limiting toxicities in breast cancer, including the use of antibody-drug conjugates and immunotherapy.

Dr Rugo on Managing Treatment-Limiting Toxicities in Breast Cancer

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers

This roundup includes exclusive insights from nearly 20 clinicians and key data on the top abstracts coming out of the 2024 ASCO Annual Meeting.

Belzutifan Yields PFS Advantage in Pretreated Advanced ccRCC Across Subgroups

Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.

Abemaciclib Monotherapy Does Not Elicit Responses in Advanced Renal Cell Carcinoma

Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.

Fianlimab Plus Cemiplimab Yields Early Efficacy Signs in Pretreated Advanced ccRCC

Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.

Belzutifan Shows Manageable, Pooled Safety Profile in Advanced VHL-Associated RCC

Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.

Dr Semaan on Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid RCC

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.

Dr McGregor on the Data for Abemaciclib in Advanced ccRCC

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Ongoing Research Aims to Identify Treatment Approaches for Non–Clear Cell RCC Subtypes

Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.

No OS Difference Observed After Various Immunotherapy/TKI Regimens in Advanced RCC

Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.

Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCC

Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.

Dr Shah on Remaining Unmet Needs in RCC After Frontline IO Combinations

Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.

Multimodal AI Approach May Help Identify Key Elements to Predict Outcomes in RCC

Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.

Nivolumab Plus Ipilimumab Yields Long-Term Efficacy Advantage in Advanced RCC

Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.